One particularly compelling strategy involves caveolin-derived peptides, such as Cavtratin, a Caveolin-1 scaffolding domain peptide, which has demonstrated potential in mitigating endothelial dysfunction and attenuating inflammation in cardiovascular and metabolic diseases. The gene discussed is CAV1; the disease is metabolic disease.